Aktienanalyse zu Fulgent Genetics Inc (FLGT)FLGTFulgent Genetics Inc

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Fulgent Genetics Inc is currently not a strong buy due to its ongoing financial struggles, with a current price of $19.61 and a negative net income of $29.53 million in Q2 2026. Although the company has a forward P/E of 7.70, indicating potential undervaluation, the recent hedge fund selling of 169.46% raises concerns about market sentiment. The stock's RSI is at 52.25, suggesting it is neither overbought nor oversold, which further supports a hold position for now.

3 analysts cover FLGT: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 32.50.